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Cannabinoid disposition in oral fluid after
controlled smoked, vaporized, and oral
cannabis administration
Madeleine J. Swortwood,a Matthew N. Newmeyer,a,b Maria Andersson,a
Osama A. Abulseoud,a Karl B. Scheidweilera* and Marilyn A. Huestisa,c
Oral fluid (OF) is an important matrix for monitoring drugs. Smoking cannabis is common, but vaporization and edible consump-
tion also are popular. OF pharmacokinetics are available for controlled smoked cannabis, but few data exist for vaporized and oral
routes. Frequent and occasional cannabis smokers were recruited as participants for four dosing sessions including one active
(6.9% Δ9-tetrahydrocannabinol, THC) or placebo cannabis-containing brownie, followed by one active or placebo cigarette, or
one active or placebo vaporized cannabis dose. Only one active dose was administered per session. OF was collected before
and up to 54 (occasional) or 72 (frequent) h after dosing from cannabis smokers. THC, 11-hydroxy-THC (11-OH-THC), 11-nor-9-
carboxy-THC (THCCOOH), tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabigerol (CBG) were quantified by liquid
chromatography-tandem mass spectrometry. OF cannabinoid Cmax occurred during or immediately after cannabis consumption
due to oral mucosa contamination. Significantly greater THC Cmax and significantly later THCV, CBD, and CBG tlast were observed
after smoked and vaporized cannabis compared to oral cannabis in frequent smokers only. No significant differences in THC, 11-
OH-THC, THCV, CBD, or CBG tmax between routes were observed for either group. For occasional smokers, more 11-OH-THC and
THCCOOH-positive specimens were observed after oral dosing than after inhaled routes, increasing % positive cannabinoid
results and widening metabolite detection windows after oral cannabis consumption. Utilizing 0.3μg/L THCV and CBG cut-offs
resulted in detection windows indicative of recent cannabis intake. OF pharmacokinetics after high potency CBD cannabis are
not yet available precluding its use currently as a marker of recent use. Published 2016. This article is a U.S. Government work
and is in the public domain in the USA.
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Introduction
Cannabis remains the most commonly used illicit drug
worldwide.[1] The main psychoactive compound in cannabis,
Δ9-tetrahydrocannabinol (THC), was detected in 12.6% of US week-
end night-time drivers’ blood or oral fluid (OF) samples[2]; increased
crash risk is associated with cannabis intake.[3–6] OF is an important
matrix for detecting drugs of abuse, particularly in driving under the
influence of drugs (DUID) testing programmes.[7–13] OF collection is
advantageous over urine and blood, as it is collected under direct
observation, deterring adulteration, without requiring specialized
collection by medical personnel. Inhalation via smoking is the most
common cannabis administration route, although inhalation via va-
porization and oral consumption via edibles frequently occurs.[14]
To date, data are available from a few OF cannabinoid disposition
studies following controlled smoked cannabis[15–20]; however,
fewer data exist after vaporized[13] and edible THC.[17,21] As inhala-
tion via vaporization and oral cannabis are becoming increasingly
popular routes of intake,[14] controlled administration studies exam-
ining these routes are crucial to understanding cannabinoid OF
pharmacokinetics. Further, ideally these routes are studied in a
within-subject, placebo-controlled design to best compare canna-
binoid pharmacokinetics.
THC is metabolized to the active metabolite 11-hydroxy-THC
(11-OH-THC), and to the inactive metabolite 11-nor-9-carboxy-
THC (THCCOOH). Concentrations for THC alone[17] and with
THCCOOH[21] were recently described in OF following an edible
cannabis brownie administration. High THC OF concentrations pri-
marily result from oral mucosa contamination during smoking or
vaporization, withminor contribution from THC that partitions from
blood into OF, especially during and shortly after intake. OF
THCCOOH concentrations vary considerably between occasional
and frequent cannabis smokers.[13,15,16] Minor cannabinoids pres-
ent in the cannabis plant include cannabinol (CBN), cannabidiol
(CBD), cannabigerol (CBG), and Δ9-tetrahydrocannabivarin (THCV).
These minor cannabinoids are possible markers of recent cannabis
intake; however, limited CBN and CBDOF concentration profiles are
available after controlled smoked[15] and vaporized[13] cannabis ad-
ministration. There are no CBN or CBD OF data after oral cannabis
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administration. Additionally, to our knowledge, OF CBG and THCV
disposition were not yet investigated.
With the increase in OF drug testing and increasing knowledge
of OF drug disposition, cut-offs and testing criteria need to be
established for clinical and forensic drug-testing programmes. For
DUID, the European Driving under the Influence of Drugs, Alcohol,
and Medicines (DRUID) project implemented a THC ≥1μg/L analyt-
ical cut-off in OF.[22] For workplace testing, the Substance Abuse
and Mental Health Services Administration (SAMHSA) proposed a
THC ≥2μg/L confirmatory cut-off in OF.[23] However, these cut-offs
need to be fully evaluated following controlled cannabis adminis-
tration via routes other than inhalation via smoking (i.e., inhalation
via vaporization or oral).
In order to fully characterize cannabinoid disposition in OF, we
investigated THC, metabolites, and minor cannabinoids in OF
(quantifying THC, 11-OH-THC, THCCOOH, THCV, CBD, and CBG) fol-
lowing controlled smoked, vaporized, and oral brownie cannabis
administration in frequent and occasional cannabis smokers. Quan-
tification of a wide spectrum of OF cannabinoids also permits as-
sessment of detection windows for parent cannabinoids and
metabolites improving interpretation of cannabinoid OF results.
Materials and methods
Participants
Healthy cannabis users (18–50 years) were recruited for this study
which has been approved by the National Institute on Drug Abuse
(NIDA) Intramural Research Program Institutional Review Board, the
Food and Drug Administration (FDA), and the Drug Enforcement
Administration (DEA). Individuals were recruited by radio and
printed advertisements and participant referrals. All participants
underwent a comprehensivemedical and psychological evaluation.
Inclusion criteria were self-reported cannabis intake ≥2x per month
but <3x per week (occasional smokers) or ≥5x per week (frequent
smokers) over the previous three months, and frequent smokers
had to produce a positive urine cannabinoid screen. Exclusion
criteria included blood pressure >140/90mmHg or heart rate
>100bpm at rest; clinically significant electrocardiogram abnor-
mality; inability to discontinue contraindicated medication before
study dosing; physical dependence on any drug other than canna-
bis, caffeine, or nicotine; medicinal cannabis use; history of clinically
significant medical or neurological illness or adverse event associ-
ated with cannabis intoxication; recent blood donation >450mL;
pregnant or nursing women; recent interest or participation in a
drug abuse treatment programme; and any history of food allergy
or sensitivity to gluten, dairy, egg, soy, and/or chocolate. Pregnancy
tests were administered at screening and on each session admis-
sion to women with reproductive potential. Individuals provided
written, informed consent before admittance to the study.
Study design
The study was randomized, double-blind, and placebo-controlled
with a crossover and double-dummy design. Participants entered
the secure research unit ~19h before dosing to preclude acute in-
toxication. Cannabis cigarettes were obtained through the NIDA
Drug Supply Program. Active cigarettes (0.734±0.05g) contained
6.9± 0.95% (~50.6mg) THC and 0.20± .01% (~1.5mg) CBD. Placebo
cigarettes (0.713±0.05 g) contained 0.001±0.000% THC andno de-
tectable CBD. Throughout four dosing sessions, participants were
administered one active or placebo brownie followed by one active
or placebo cigarette or one active or placebo vaporized ground
cannabis dose (210 °C, Volcano® Medic, Storz & Bickel, Tuttlingen,
Germany). Nomore than one active dose was administered per ses-
sion and the oral dose was followed by either smoking or vaporiza-
tion in two sessions each. Participants had 10min to consume the
oral dose ad libitum followed by 10min to consume the inhaled
dose ad libitum. Frequent smokers remained on the unit 72 h
post-dose and were required to leave the unit for ≥72h before be-
ing admitted to their next session. Occasional smokers remained on
the unit 54 h post-dose but had the option of remaining on the unit
for multiple sessions; they were not dosed more frequently than
their self-reported intake frequency.
Brownies were prepared with Duncan Hines® double fudge
brownie mix according to the manufacturer’s instructions and wet
batter was portioned into a muffin tray. The contents of either an
active or placebo cigarette were ground, placed into a greased foil
packet, and baked at 121 °C for 30min to ensure decarboxylation of
the acid precursor to THC, then mixed into an individual portion of
brownie batter. After cooling, brownies were stored at -20 °C until
the night before dosing, and thawed at 4 °C.
OF specimens were collected with the QuantisalTM device
(Immunalysis, Pomona, CA, USA), which has a volume adequacy in-
dicator for 1.0± 0.1mL OF. OF was collected until the indicator
turned blue or 5min elapsed, whichever occurred first due to the
tight timeline. Oral intake was prohibited 10min prior to OF collec-
tion. OF was collected on admission (-19 h), 1.5 h before the initia-
tion of smoking/vaporization (baseline, -1.5h) and at 0.17, 1.5, 3.5,
5, 8, 10, 12, 14, 20, 26, 32, 38, 44, and 50h after
smoking/vaporization initiation, and at 54 h for occasional smokers
only, and at 56, 62, 68, and 72h for frequent smokers only.
Oral fluid analysis
Specimens were placed in 3mL elution/stabilizing buffer at 4 °C for
>12h prior to pad removal, followed by transfer of OF/buffer to
polypropylene cryotubes and storage at 4 °C until analysis. Speci-
mens were analyzed within 1month of collection based on our pre-
vious OF cannabinoid stability study[24,25] and quantified for THC,
THCCOOH, 11-OH-THC, THCV, CBD, and CBG by a previously pub-
lished method.[26] Briefly, samples (1mL elution buffer OF mixture
containing 0.25mLOF) were mixed with 0.3mL 1M ammonium ac-
etate buffer (pH4) and hydrolyzed with 625 Units of β-
glucuronidase (BG100®, Kura Biotec, Puerto-Varas, Chile), acidified
and extracted with cation exchange solid-phase columns. Cannabi-
noids were quantified by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) using atmospheric pressure chemical
ionization with 0.2μg/L limits of quantification (except 15ng/L
THCCOOH). Inter-assay accuracy and imprecision were 88.1–106%
and 5.8–8.2%CV, respectively (n = 92). Samples quantifying greater
than the upper limits of quantification were re-analyzed after dilu-
tion with OF/buffer.
Data analysis
Differences in demographic data between groups were evaluated
with t-tests. Maximum concentration (Cmax), time to Cmax (tmax),
and time of last detection (tlast) were calculated with concentrations
observed post-dose and differences between administration routes
were assessed with SPSS® Statistics 23 for Windows (IMB, Armonk,
NY, USA). For analytes detected after all three routes, differences
were evaluated by repeated-measures ANOVA with separation of
frequent and occasional smokers. If sphericity was violated, the
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Greenhouse-Geisser correction was utilized. If a significant route ef-
fect was observed, planned Helmert contrasts were performed first
by comparing mean oral dose to the combined mean of inhaled
doses then comparing smoking to vaporization. Smoking group dif-
ferences (frequent vs. occasional) were evaluated with separate
repeated-measures ANOVA, with group included as a between-
subject factor; if a significant route*group interaction was observed,
then group differences after each administration route were evalu-
ated with t-tests. Significance was attributed to a two-tailed
p< 0.05.
Results
Participants
Demographics for 11 frequent and 9 occasional cannabis smokers
are summarized in Table 1. Participants were 19–46 years old,
75% male and 75% African American. Participant K was originally
admitted as an occasional smoker, but later reclassified as a fre-
quent smoker based on baseline and post-dose blood cannabinoid
pharmacokinetics. Participant H smoking frequency at admission to
Session 1 was inconsistent with self-reported frequency at screen-
ing so his demographic data were not included in summary statis-
tics; smoking frequencies reported on admission to subsequent
sessions were consistent with self-reported frequency at screening.
Frequent smokers were all African American, began smoking at a
significantly younger age, smoked significantly more frequently
over the previous 14days, and smoked significantly more per
smoking occasion.
In total, 1102 OF specimens (598 frequent, 504 occasional) were
analyzed. OF specimens were not collected from 56 to 72h for par-
ticipant K because he was originally recruited as an occasional
smoker.
Pharmacokinetic evaluation
Pharmacokinetic parameters and statistical evaluations for cannabi-
noids and metabolites are summarized in Table 2 for analytes de-
tected after all three routes. Time course profiles for all six
analytes in frequent and occasional smokers following three
Table 1. Demographic data and cannabis smoking histories for 11 frequent and 9 occasional smokers.
Participant Sex Age
(years)
Racea BMI
(kg/
m2)
Age at
first useb
(years)
Lifetime
Years
Smokedb
Cannabis
Intake
Frequencyb
Time between last
use and admissionc
Number of days
used in last 14c
Average joint or joint
equivalent per smoking
occasionc
Frequent Smokers
A M 21 AA 26.5 16 5 Daily 17.2 h 14 5
B M 22 AA, U 31.0 15 7 Daily 19.3 h 10 4
C M 19 AA 19.8 13 6 Daily 18.7 h 14 4
D F 23 AA 31.9 13 10 Daily 7.9 h 14 10
E M 38 AA 32.2 12 26 Daily 2.4 h 14 15
F F 29 AA 31.0 11 18 Daily 1.9 h 14 20
G M 38 AA 22.0 16 22 Daily 2.1 h 14 7
H M 34 AA 23.0 14 20 5x/week 239.7 hd 2d 2d
I M 21 AA 25.0 11 10 Daily 0.7 h 14 5
J M 25 AA 19.0 13 12 5x/week 5.8 h 14 2
K M 31 AA 16.8 15 16 2-3x/weeke 5.1 he 4e 2.5e
Mean 27.4 f 25.3 13.5f 13.9 8.4 h 13.6f 8.0f
SD 6.9 5.6 1.8 6.9 7.8 h 1.3 6.0
Median 25.3 25.0 13.0 12.3 5.8 h 14.0 5.0
Occasional Smokers
L M 24 AA 36.3 17 7 2x/month 1.4 days 3 2
M M 21 AA 23.0 13 8 2x/week 0.7 days 4 2
N M 25 W 24.2 21 4 2x/week 13.0 days 1 3
O M 40 W 28.3 18 22 2x/week 30.7 days 0 2
P F 46 AA 31.0 26 20 2x/week 0.4 days 4 4
Q M 33 AA 30.7 16 17 2x/month 22.8 days 0 3
R F 22 W 22.0 16 6 2x/week 1.7 days 4 1
S F 22 W 23.0 14 8 2x/week 1.1 days 10 2
T M 31 W 21.7 22 9 1-2x/week 1.8 days 2 2
Mean 29.4 f 26.7 18.1f 11.3 8.2 days 3.1f 2.3f
SD 8.6 5.1 4.2 6.3 11.4 days 3.1 0.9
Median 24.9 24.2 17.0 8.5 1.7 days 3.0 2.0
aAA, African American; W, white; U, unknown
bData collected during screening
cData collected on admission to Session 1
dSelf-reported data on admission inconsistent with data received at screening. Data excluded from statistics.
eSelf-reported data inconsistent with biological sample concentrations. Data excluded from statistics.
fSignificant difference between groups (p< 0.05)
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Table 2. Summary of mean (range), maximum cannabinoid analyte concentrations (Cmax), time to Cmax (tmax), and time of last positive (tlast) after
smoked, vaporized and oral cannabis doses (6.9%Δ9-tetrahydrocannabinol, THC; ~50.6mg THC) in 11 frequent and 9 occasional smokers. Repeated-mea-
sures analysis of variance F-statistic and p-value for overall route effect and planned Helmert contrasts are reported (contrast 1 evaluated the difference
between the variance from oral dosing and the combined variance from smoked and vaporized dosings, contrast 2 evaluated the difference in variances
from smoked and vaporized dosing). Route-specific significant differences between smoking groups were calculated and annotated in table. Only par-
ticipants whose oral fluid was positive for analytes after all cannabis administrations were included in analyses.
Analyte and
Parameter
N Oral Smoking Vaporization F p Contrast 1 Contrast 2
F p F p
THC
Frequent Smokers
Cmax, μg/L 11 297 (16.5-938) 2789 (141-8503) 1874 (68.6-7373) 3.60 0.046 11.63 0.007 0.648 0.440
tmax, h 11 0.41 (0.17-1.5) 0.17 0.17 2.22 0.167 - - - -
tlast, h
a 10 55.0 (20- >72) 61.0 (32- >72) 55.4 (26- >72) 0.80 0.463 - - - -
Occasional Smokers
Cmax, μg/L 9 202 (65-380) 837 (81.4-5914) 545 (7.6-3279) 1.00 0.388 - - - -
tmax, h 9 0.32 (0.17-1.5) 0.17 0.32 (0.17-1.5) 0.47 0.633 - - - -
tlast, h 9 24.7 (10- >54) 24.7 (8-50) 18.6 (5- >54) 2.37 0.126 - - - -
11-OH-THC
Frequent Smokers
Cmax, μg/L 1 0.23 2.2 0.27 - - - - - -
tmax, h 1 0.17 0.17 0.17 - - - - - -
tlast, h 1 0.17 0.17 0.17 - - - - - -
Occasional Smokers
Cmax, μg/L 0 - - - - - - - - -
tmax, h 0 - - - - - - - - -
tlast, h 0 - - - - - - - - -
THCCOOH§
Frequent Smokers
Cmax, μg/L 11 0.40 (0.13-1.2) 0.41 (0.13-1.2) 0.37 (0.05-0.97) 0.09 0.911 - - - -
tmax, h 11 25.7 (0.17-68) 14.2 (0.17-68) 8.4 (0.17-20) 4.29 0.028 7.41 0.021 0.96 0.351
tlast, h
a 10 71.6 (68- >72) 66.6 (44- >72) 66.6 (44- >72) 1.74 0.204 - - - -
Occasional Smokers
Cmax, μg/L 3 0.35 (0.02-0.80) 0.18 (0.12-0.31) 0.09 (0.02-0.17) 0.96 0.457 - - - -
tmax, h 3 8.5 (3.5-14) 0.17 6.8 (0.17-20) 0.84 0.498 - - - -
tlast, h 3 38.7 (8- >54) 15.7 (1.5-44) 18.6 (0.17- >54) 1.89 0.265 - - - -
THCV
Frequent Smokers
Cmax, μg/L 11 4.5 (0.26-14.5) 28.3 (1.6-82.4) 40.2 (1.8-159) 2.74 0.117 - - - -
tmax, h 11 0.53 (0.17-1.5) 0.29 (0.17-1.5) 0.17 1.89 0.193 - - - -
tlast, h 11 1.7 (0.17-3.5) 4.7 (1.5-12)* 3.9 (1.5-8) 5.25 0.015 17.78 0.002 0.47 0.510
Occasional Smokers
Cmax, μg/L 7 3.5 (1.2-5.6) 34.3 (1.0-146) 17.5 (0.30-82.4) 1.63 0.237 - - - -
tmax, h 7 0.36 (0.17-1.5) 0.17 0.17 1.00 0.356 - - - -
tlast, h 7 2.7 (0.17-5) 1.7 (0.17-8)* 2.8 (0.17-8) 0.647 0.541 - - - -
CBD
Frequent Smokers
Cmax, μg/L 11 8.0 (0.48-26.3) 93.3 (0.65-350) 76.3 (2.3-339) 2.92 0.077 - - - -
tmax, h 11 0.53 (0.17-1.5) 0.29 (0.17-1.5) 0.29 (0.17-1.5) 1.00 0.386 - - - -
tlast, h 11 2.2 (1.5-3.5) 8.1 (1.5-20) 7.4 (3.5-20) 5.40 0.013 21.55 0.001 0.09 0.769
Occasional Smokers
Cmax, μg/L 9 5.9 (2.1-11.4) 55.9 (2.5-291) 28.2 (0.23-167) 1.731 0.209 - - - -
tmax, h 9 0.47 (0.17-1.5) 0.17 0.17 2.29 0.169 - - - -
tlast, h 9 2.9 (1.5-5) 4.0 (0.17-20) 3.6 (0.17-20) 0.19 0.728 - - - -
CBG
Frequent Smokers
Cmax, μg/L 11 17.0 (0.77-60.6) 165 (5.7-441) 87.4 (2.7-394) 4.63 0.022 10.56 0.009 1.87 0.201
tmax, h 11 0.41 (0.17-1.5) 0.17 0.17 2.22 0.167 - - - -
tlast, h 11 3.0 (1.5-8) 10.6 (5-20) 5.4 (1.5-8) 8.64 0.002 15.52 0.003 5.64 0.039
(Continues)
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administration routes are shown in Figures 1 and 2. THCCOOH con-
centrations represent free and hydrolyzed glucuronide concentra-
tions. THC-glucuronide present in OF would also be hydrolyzed
by this method (67% efficiency)[26] but biological concentrations
are considered negligible based on previous research.[27]
Observed mean THC, 11-OH-THC, THCV, CBD, and CBG tmax
occurred at or before the first OF collection (0.17 h) immediately
at the completion of cannabis intake, followed by rapid
concentration decreases for frequent and occasional smokers after
all routes of administration. There were no significant differences in
THC, 11-OH-THC, THCV, CBD, and CBG tmax between routes. Fre-
quent smokers’ THCCOOHmean (range) tmax was significantly later
after oral dosing (25.7 [0.17–68] h) compared to smoking
(14.2 [0.17–68] h) and vaporization (8.4 [0.17–20] h), as described in
Table 2, Contrast 1. Only three occasional smokers were THCCOOH
positive after all routes of administration; however, all occasional
Table 2. (Continued)
Analyte and
Parameter
N Oral Smoking Vaporization F p Contrast 1 Contrast 2
F p F p
Occasional Smokers
Cmax, μg/L 9 11.9 (3.2-26.3) 118 (5.4-602) 24.4 (0.30-142) 2.19 0.176 - - - -
tmax, h 9 0.47 (0.17-1.5) 0.17 0.17 2.29 0.169 - - - -
tlast, h 9 3.7 (1.5-10) 4.9 (0.17-26) 3.2 (0.17-20) 0.63 0.465 - - - -
THC, Δ9-tetrahydrocannabinol; 11-OH-THC, 11-hydroxy-THC; THCCOOH, 11-nor-9-carboxy-THC; THCV, Δ9-tetrahydrocannabivarin; CBD, cannabidiol; CBG,
cannabigerol; bolded p-values designate significance
*denotes route-specific significant difference between smoking groups (two-tailed t-test p< 0.05)
aN = 10 because participant K (originally recruited as an occasional smoker, therefore oral fluid was only collected up to 54 h post-dose) was still positive at
the final collection.
§total THCCOOH (free + hydrolyzed glucuronide)
Figure 1. Mean+ standard deviation (SD) concentrations on a log-scale for Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-
carboxy-THC (THCCOOH) in n = 11 frequent (left) and n = 9 occasional (right) smokers up to 72 and 54 h, respectively, after smoked, vaporized, and oral
cannabis (6.9% Δ9-tetrahydrocannabinol, THC; ~50.6mg THC) administration (0 h). Horizontal lines present at the limits of quantification (LOQ; 0.2μg/L for
all, except 15 ng/L for THCCOOH) and OF THC cut-offs for DRUID (1μg/L) and SAMHSA (2μg/L).
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smokers were positive after the oral dose. 11-OH-THC was only
detected in one frequent smoker after all doses; however,
11-OH-THC was present in 10/11, 2/11, and 4/11 frequent smokers
after the smoked, vaporized, and oral doses, respectively. 11-OH-
THC was detected in 3/9, 0/9, and 6/9 occasional smokers after
smoked, vaporized, and oral cannabis administration. CBD and
CBG were detected in all participants after all administrations, while
THCVwas detected in all frequent smokers and 9/9, 7/9, and 9/9 oc-
casional smokers after smoked, vaporized, and oral cannabis.
Frequent smokers’ mean THC and CBG Cmax were significantly
greater after inhaled routes than after oral cannabis; no difference
was observed between smoked and vaporized cannabis. Mean
(range) THC Cmax in frequent smokers after smoked (2789
[141–8503] μg/L) and vaporized (1874 [68.6–7373] μg/L) cannabis
were significantly higher than in occasional smokers after smoked
(837 [81.4–5914] μg/L) and vaporized (545 [7.6–3279] μg/L) canna-
bis. Mean (range) THC Cmax after oral administration for frequent
and occasional smokers were 297 (16.5–938) and 202 (65.0–380)
μg/L, respectively. Overall, frequent smokers’ observed THC Cmax
were significantly greater than those in occasional smokers’, regard-
less of route; no statistically significant route*group interactions
were observed.
Frequent smokers’ mean (range) THCV, CBD, and CBG tlast were
significantly later after smoked (4.7 [1.5–12], 8.1 [1.5–20], and 10.6
[5–20] h, respectively) and vaporized (3.9 [1.5–8], 7.4 [3.5–20], and
5.4 [1.5–8] h respectively) cannabis compared to oral (1.7
[0.17–3.5], 2.2 [1.5–3.5], and 3 [1.5–8] h, respectively) administration.
Minor cannabinoids THCV, CBD, and CBG were never detected
beyond 26h in any participant after any administration route;
CBD (up to 20h) and CBG (up to 26h) were detected longer than
THCV (up to 12h). For frequent smokers, the only significant differ-
ence between inhaled routes was a later CBG tlast after smoked can-
nabis compared to the vaporized dose. Cannabinoid tlast in
occasional smokers were not significantly different between
smoked and vaporized administration. When comparing groups, a
significantly later THCV tlast was observed for frequent smokers after
smoking compared to occasional smokers.
At their final collection time (72 h), 6/11, 3/11, and 2/11 frequent
smokers were still THC positive at 0.2–2.2, 0.2–0.6, 0.3–0.5μg/L after
smoked, vaporized, and oral cannabis, respectively. Only one occa-
sional smoker was THC positive at the final collection time (54 h)
after the vaporized and oral sessions, with 0.2 and 0.4μg/L, respec-
tively; this participant had the largest Cmax in these sessions among
occasional smokers. Overall, frequent smokers’ THC tlast was signif-
icantly later than occasional smokers’, regardless of route; no statis-
tically significant route*group interactions were observed.
THCCOOH was present at discharge in 8/11, 7/11, and 10/11 fre-
quent smokers and 0/9, 1/9, and 2/9 occasional smokers after
smoked, vaporized, and oral cannabis, respectively. Occasional par-
ticipants P and S with THCCOOH concentrations> LOQ (limit of
quantification) at discharge were also THCCOOH positive at admis-
sion (-19 h) and baseline (-1.5 h) to the same session, with
Figure 2. Mean+ standard deviation (SD) concentrations (up to 20 h) for Δ9-tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabigerol (CBG) in
n = 11 frequent (left) and n = 9 occasional (right) smokers after smoked, vaporized, and oral cannabis (6.9% Δ9-tetrahydrocannabinol, THC; ~50.6mg THC)
administration (0 h). Horizontal lines present at the limits of quantification (0.2μg/L for all)
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THCCOOH concentrations at admission comparable to those at dis-
charge. THCCOOH tlast was significantly later in frequent smokers
compared to occasional smokers, regardless of administration
route. 11-OH-THC was detected infrequently and never beyond
1.5h in any participant after any administration route.
Cannabinoid detection rates
THC detection rates at three cut-offs (LOQ 0.2μg/L, DRUID 1μg/L,
and SAMHSA 2μg/L) for frequent and occasional smokers are
found in Figure 3. At the LOQ, DRUID, and SAMHSA cut-offs, THC
was still observed in frequent smokers’ OF samples at discharge
(72h), with detection rates never reaching 0%. At the LOQ, one
occasional smoker’s OF samples were still THC positive at discharge
(54h), while all samples were below DRUID and SAMHSA THC cut-
offs by 50 and 32h, respectively. Detection rates dropped more
quickly following oral administration. One frequent smoker was
THC positive (2.2μg/L) above DRUID and SAMHSA cut-offs when
discharged 72h after smoking. At baseline (-1.5h), following an
overnight stay on the controlled research unit, 11/11, 9/11, and
10/11 frequent smokers remained positive for THC above DRUID
cut-off (1μg/L) prior to smoked, vaporized, and oral cannabis
sessions, respectively. Of the frequent smokers THC positive at
baseline, all except four samples’ THC concentrations were also
above the SAMHSA THC cut-off (2μg/L) prior to a dosing session.
At baseline, only one occasional smoker was THC positive above
the SAMHSA cut-off prior to smoking (14.3μg/L) and oral
(10.6μg/L) sessions.
THCV, CBD, and CBG detection rates at the LOQ (0.2μg/L) for fre-
quent and occasional smokers are found in Figure 4. More frequent
than occasional smokers were positive for the minor cannabinoids
after all routes, since THCV was not detected after vaporization in
some occasional smokers. At the LOQ, frequent smokers were no
longer positive for THCV, CBD, and CBG at 14, 26, and 26h, respec-
tively, and 10, 26, and 32h for occasional smokers. Frequent
smokers’ detection rates were highest for the longest amount of
time after smoked cannabis administration, as smoking produced
slightly higher cannabinoid concentrations compared to vaporized
and oral doses. Detection rates between frequent and occasional
smokers were similar for minor cannabinoids following vaporized
and oral administration.
In order to establish detection windows reflecting use within the
last 24h, different cut-offs were investigated for theminor cannabi-
noids. THCV, CBD, and CBG detection rates at proposed 0.3, 0.5, and
0.3μg/L cut-offs, respectively, for frequent and occasional smokers
are found in Figure 5. At these cut-offs, THCV, CBD, and CBG were
no longer detected in frequent smokers OF samples at 10, 26, and
26h, respectively, and 10, 14, and 26h for occasional smokers. De-
tection rates between frequent and occasional smokers were simi-
lar for minor cannabinoids at 0.3–0.5μg/L cut-offs.
Discussion
For the first time, we present parent cannabinoid (THC, THCV, CBD,
and CBG) and metabolite (11-OH-THC and THCCOOH) disposition
Figure 3. Δ9-tetrahydrocannabinol (THC) detection rates (%) at three cut-offs: limit of quantification (0.2μg/L, LOQ), DRUID (1 μg/L), and SAMHSA (2μg/L) for
n = 11 frequent (left) and n = 9 occasional (right) smokers up to 72 and 54 h, respectively, after smoked, vaporized, and oral cannabis (6.9% Δ9-
tetrahydrocannabinol, THC; ~50.6mg THC) administration (0 h).
Oral fluid cannabinoids after three routes of cannabis administration
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in OF following controlled smoked, vaporized, and oral (brownie)
cannabis administration utilizing a within-subject study design for
11 frequent and 9 occasional cannabis smokers. Cannabinoid phar-
macokinetics are well studied in OF following smoked[9,15,16] ad-
ministration of cannabis, while clinical data following vaporized[13]
and edible[17,21] cannabis are limited.
THC, THCV, CBD, and CBG tmax indicate oral mucosa contamina-
tion from cannabis intake that is observed at the first OF collection
time point. 11-OH-THC also appeared immediately (0.17h) in a few
cases suggesting possible THC metabolism in the oral mucosa. Cy-
tochrome P450 enzymes were identified in human oral tissue
cells[28–31] and could contribute to the presence of metabolites in
OF. 11-OH-THC was rarely detected after all administration routes
and never beyond 1.5h post-dose. 11-OH-THC was detected more
frequently after smoking in this study compared to previous studies
due to our lower LOQ (0.2 vs. 0.5μg/L). Most observed 11-OH-THC
concentrations would have been missed with previous analytical
methods. THCCOOH appeared immediately (0.17 h) in a few occa-
sional smokers’ OF after inhaled routes but more frequently and
for longer periods of time after oral intake. Among occasional
smokers THCCOOH positive at 0.17 h (4/9, 3/9, and 7/9 after
smoked, vaporized, and oral doses, respectively), concentrations
were greater than those at baseline in all but one case, suggesting
THCmetabolism in the oral mucosa and/or partitioning from blood.
THCCOOH concentrations remained elevated in frequent smokers’
OF throughout the sessions, although the tmax also was delayed af-
ter oral administration, similar to the pattern observed in occasional
smokers. A significantly later THCCOOH tmax also occurred in blood
specimens from the same cohort following oral cannabis adminis-
tration, supporting blood-OF partitioning. Similarly, Vandrey et al.
observed delayed mean (range) OF THCCOOH tmax of 9.8 (3–30)
and 17.4 (0–54) h following consumption of 25 and 50mg oral
THC (brownie), respectively.[21]
Frequent smokers’ THC Cmax after smoking a 6.9% THC cannabis
cigarette in the present study were higher than those reported pre-
viously for similar potency cannabis,[15,16] but our initial OF collec-
tion time post-dose (0.17 vs. 0.5h) was earlier. However, Toennes
et al. collected OF 0.08 h after smoking a 500μg THC/kg cannabis
cigarette and observed higher median (range) THC Cmax of 6202
(387-71 147) and 1242 (397–6438) ng/g in frequent and occasional
smokers, respectively.[9] Occasional smokers’ median THC Cmax in
the present study were lower than those previously reported[15,16]
but exhibited a wider range, which could be influenced by smoking
history, topography, and possible titration. We observed lower me-
dian (range) THC concentrations for both groups of smokers com-
pared to moderate smokers’ THC Cmax following vaporization of
500mg 6.7% THC ground cannabis.[13] Differences in THC Cmax after
vaporization in this study could be due to differences in smoking
history, inhalation topography, and titration. Additionally, less effi-
cient cannabinoid vaporization can occur with increased plant
material,[32] as we vaporized ~750mg ground cannabis compared
to 500mg in Hartman et al. Although no statistically significant dif-
ferences in Cmax between smoking and vaporization were
observed, differences in heating temperature could potentially
Figure 4. Δ9-tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabigerol (CBG) detection rates (%) up to 32 h at the limits of quantification
(0.2 μg/L) for n = 11 frequent (left) and n = 9 occasional (right) smokers after smoked, vaporized, and oral cannabis (6.9% Δ9-tetrahydrocannabinol, THC;
~50.6mg THC) administration (0 h)
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release fewer cannabinoids during vaporization compared to
smoking, although less pyrolysis of THC would be expected and
there is no loss of THC in side-stream smoke as occurs during
smoking. In addition, vaporization stores THC vapour in a plastic
bag during heating, possibly losing small amounts of THC through
absorption to the bag.
Frequent and occasional smokers’ THC Cmax following oral con-
sumption were not significantly different, as this route is not ame-
nable to self-titration. Our mean THC Cmax were lower than those
reported by Vandrey et al. following 25 or 50mg oral (brownie)
THC in drug-free users (n= 6) but were more similar to those
reported for 10mg oral THC in the same study.[21] Observed differ-
ences in oral THC concentrations could be due to our later collec-
tion time (0.17h post-inhalation dose, equating to 0.33h post-oral
dose compared to their 0.2 h time point). In a separate study,
Niedbala et al. reported 2.2–7.1μg/L THC 1–2h after oral brownie
consumption (20–25mg THC) in casual users (n= 3).[17] By 1.5 h
post-dose in our study, THC concentrations after oral cannabis were
much greater (10.8–938 and 23.0–256μg/L in frequent and occa-
sional smokers, respectively) than Niedbala’s reported THC concen-
trations at the same time post-dose; this may be due to a
combination of different brownie preparations (i.e., how well the
precursor Δ9-tetrahydrocannabinolic acid is converted to THC dur-
ing baking) and our higher-potency THC variety. Compared to oral
synthetic THC (dronabinol, Marinol®) administration, we observed
increases in THC OF concentrations post-dose due to oral cavity
contamination that did not occur with encapsulated synthetic oral
THC (dronabinol).[33,34]
THC and CBG exhibited significantly higher concentrations in
frequent smokers’ OF after inhaled routes than after oral cannabis
dosing. Smoked and vaporized cannabis administration were
previously reported to produce similar cannabinoid OF
concentrations[13]; this was observed, except for a later CBG tlast af-
ter smoked cannabis compared to the vaporized dose. However,
due to the greater CBG concentrations after smoked compared to
vaporized cannabis, this could be expected. The same trend was
observed with CBG disposition in whole blood and could be
explained by inefficient CBG volatilization during vaporization. Sig-
nificantly later tlast forminor cannabinoids in frequent smokers after
inhaled cannabis could be due to the much greater concentrations
achieved compared to brownie consumption. Differences in Cmax
between the routes were not anticipated amongst occasional
smokers as they often exhibit inefficient smoking/vaporization
topography, leading to lower cannabinoid concentrations after
inhalation similar to those following oral administration. Lower OF
THC concentrations achieved after oral cannabis compared to
inhaled cannabis could be due to oral intake mechanism (chewing
and swallowing may not release as much THC as inhaling), ad
libitum study design, conversion to CBN, degradation during
baking, or possibly less efficient decarboxylation of acid to THC.
Cannabinoid metabolite detection and interpretation in OF can
be complicated. 11-OH-THC is detected infrequently and only for
Figure 5. Δ9-tetrahydrocannabivarin (THCV), cannabidiol (CBD), and cannabigerol (CBG) detection rates (%) up to 26 h at the proposed cut-offs (0.3, 0.5, and
0.3μg/L, respectively) for n = 11 frequent (left) and n = 9 occasional (right) smokers after smoked, vaporized, and oral cannabis (6.9% Δ9-
tetrahydrocannabinol, THC; ~50.6mg THC) administration (0 h).
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a short period of time. While detection of 11-OH-THC in oral fluid is
an indication of recent cannabis use, its absence does not preclude
recent consumption. OF THCCOOH concentration variability ob-
served in this study was also previously observed.[13,15,16]
For the first time, THCV and CBG disposition were characterized
in OF for frequent and occasional smokers following controlled
smoked, vaporized, and oral (brownie) cannabis consumption with
similar detection rates between groups and routes. Previously,
THCV and CBG disposition were only described in urine.[35–37] Mean
THCV Cmax (tmax) were 17.5–40.2μg/L (0.17–0.29h) after inhalation
routes and 3.2–4.5μg/L (0.47–0.53 h) after oral dosing among all
participants, while mean CBG Cmax (tmax) were 87.4–244μg/L
(0.17h) after inhaled routes and 11.9–17.0μg/L (0.41–0.47 h) after
oral dosing for all participants. In our cohort, both THCV and CBG
were detected in 11/11 frequent and 7/9 occasional (THCV) and
11/11 frequent and 9/9 occasional (CBG) smokers after all adminis-
tration routes for up to 26h at the LOQ of 0.2μg/L, making them
applicable for identifying cannabis intake within about one day,
as previously suggested by Desrosiers et al.[26] THCV was not de-
tected in two occasional smokers after vaporization with low THC
concentrations (7.5 and 8.5μg/L at 0.17 h). CBD was previously in-
vestigated in OF following smoked[15] and vaporized[13] cannabis
administration in different cohorts. While CBD Cmax after smoking
in this study (0.17–0.29 h) were slightly higher than those observed
in frequent and occasional smokers 0.5 h after smoking,[15] our me-
dian occasional smokers’ CBD Cmax after vaporization were compa-
rable to those reported for moderate smokers after the high THC
dose without alcohol in Hartman et al. vaporization study.[13] To
our knowledge, CBD was not previously investigated in OF follow-
ing oral cannabis administration. CBD, while a useful marker of re-
cent use in this study, cannot be thoroughly characterized until
investigated at the higher-potency CBD cannabis material now
available in the market.
DRUID and SAMHSA established THC OF confirmation cut-off
guidelines of 1 and 2μg/L, respectively. However, frequent
smokers’ THC concentrations remain well above these cut-offs for
longer periods of time, making data interpretation difficult for esti-
mating recent use. Occasional smokers’ OF THC concentrations are
generally lower and may fall below the DRUID or SAMHSA cut-offs
within a much shorter timeframe, making it difficult to capture re-
cent use beyond several hours. OF THC concentrations after oral
cannabis consumption are not as high as concentrations observed
following inhaled routes and concentrations fall below DRUID and
SAMHSA cut-offs much more quickly. Additionally, THC peak con-
centrations in OF following edible cannabis consumption occur
prior to peak impairment, with no secondary peak after oral con-
sumption, suggesting oral mucosa contamination rather than
partitioning from blood.
In order to establish detection windows for capturing recent
cannabis use, we previously investigated several combinations of
cut-offs, including THC in combination with CBD, CBN, and/or
THCCOOH.[13,15,16] Our new expanded OF cannabinoid method in-
corporates THCV and CBG as additional analytes, although CBN
could no longer be included as we could not chromatographically
separate it from a matrix interference. Our low LOQs for minor can-
nabinoids, including THCV and CBG, allowed us to detect these
analytes up to 26h following controlled cannabis administration.
By applying a 0.3μg/L cut-off for THCV or CBG, detection windows
were 8 and 20h, respectively, for both frequent and occasional
smokers. Monitoring minor cannabinoids in OF offers the ability
to detect recent cannabis use that is not achievable for THC
and/or THCCOOH. However, minor cannabinoids (THCV, CBN,
CBD, and CBG) were not detected in whole blood specimens col-
lected from the same cohort following oral brownie administration
(manuscript under review). While these data offer promising results
for capturing recent cannabis use by increasing the cannabinoids
analyzed in OF specimens, more research is necessary following
other administration routes, including vape pens, dabs, waxes,
THC oils, and other cannabis and/or THC products. Comparison to
pharmacodynamic outcomes as well as on-site OF screening de-
vices and other matrices would assist in further interpretation of
OF cannabinoid data.
Conclusions
THC, metabolites, and minor cannabinoids were fully characterized
in OF following controlled cannabis brownie consumption with di-
rect comparison to smoked and vaporized administration in the
same frequent and occasional smokers. The within-subject study
design allowed for direct pharmacokinetic comparisons between
the different administration routes. Few differences were observed
between smoked and vaporized cannabis administrations. For the
first time, THCV and CBG were characterized in OF after multiple
routes and CBD was characterized for the first time after oral canna-
bis administration. Cannabinoid concentrations peaked immedi-
ately after cannabis consumption, regardless of route, as a result
of oral mucosa contamination. As expected, greater THC concentra-
tions were observed after smoked and vaporized cannabis com-
pared to oral administration. Minor cannabinoids, including THCV,
CBD, and CBG, were detected in 18/20, 20/20, and 20/20 study par-
ticipants, respectively, after all three administration routes and up
to 26h post-dose, indicating potential utilization as markers of can-
nabis use within 1 day that could be helpful in interpretation of clin-
ical and forensic drug testing programmes.
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